References
1. Cresci S, Pereira NL, Ahmad F, Byku M, de Las Fuentes L, Lanfear DE, et al. Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association. Circ Genom Precis Med. 2019;12(10):458-85.
2. Hung CL, Chao TF, Su CH, Liao JN, Sung KT, Yeh HI, et al. Income level and outcomes in patients with heart failure with universal health coverage. Heart. 2020.
3. Clerkin KJ, Garan AR, Wayda B, Givens RC, Yuzefpolskaya M, Nakagawa S, et al. Impact of Socioeconomic Status on Patients Supported With a Left Ventricular Assist Device: An Analysis of the UNOS Database (United Network for Organ Sharing). Circ Heart Fail. 2016;9(10).
4. Theochari CA, Michalopoulos G, Oikonomou EK, Giannopoulos S, Doulamis IP, Villela MA, et al. Heart transplantation versus left ventricular assist devices as destination therapy or bridge to transplantation for 1-year mortality: a systematic review and meta-analysis. Ann Cardiothorac Surg. 2018;7(1):3-11.
5. Breathett K. Same Story, Different Disease: It Is Time to Change the Storyline for Racial Minorities and Patients of Lower Socioeconomic Status. Circ Heart Fail. 2018;11(3):e004931.
6. Hawkins NM, Jhund PS, McMurray JJ, Capewell S. Heart failure and socioeconomic status: accumulating evidence of inequality. Eur J Heart Fail. 2012;14(2):138-46.
7. Chair SY, Yu DS, Ng MT, Wang Q, Cheng HY, Wong EM, et al. Evolvement of left ventricular assist device: the implications on heart failure management. J Geriatr Cardiol. 2016;13(5):425-30.
8. Sanaiha Y, Downey P, Lyons R, Nsair A, Shemin RJ, Benharash P. Trends in utilization, mortality, and resource use after implantation of left ventricular assist devices in the United States. J Thorac Cardiovasc Surg. 2020.
9. Tchoukina I, Shah KB, Thibodeau JT, Estep JD, Lala A, Lanfear DE, et al. Impact of Socioeconomic Factors on Patient Desire for Early LVAD Therapy Prior to Inotrope Dependence. J Card Fail. 2020;26(4):316-23.
10. Grady KL, Sherri W, Naftel DC, Myers S, Gelijins A, Moskowitz A, et al. Age and gender differences and factors related to change in health-related quality of life from before to 6 months after left ventricular assist device implantation: Findings from Interagency Registry for Mechanically Assisted Circulatory Support. J Heart Lung Transplant. 2016;35(6):777-88.
11. Gupta RP, de Wit ML, McKeown D. The impact of poverty on the current and future health status of children. Paediatr Child Health. 2007;12(8):667-72.
12. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018;137(20):2166-78.
13. Carnethon MR, Pu J, Howard G, Albert MA, Anderson CAM, Bertoni AG, et al. Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association. Circulation. 2017;136(21):e393-e423.
14. Graham G. Disparities in cardiovascular disease risk in the United States. Curr Cardiol Rev. 2015;11(3):238-45.
15. Flint KM, Matlock DD, Lindenfeld J, Allen LA. Frailty and the selection of patients for destination therapy left ventricular assist device. Circ Heart Fail. 2012;5(2):286-93.
16. Breathett K, Allen LA, Helmkamp L, Colborn K, Daugherty SL, Blair IV, et al. Abstract 168: Racial and Ethnic Differences in Contemporary Use of Left Ventricular Assist Device. Circulation: Cardiovascular Quality and Outcomes. 2017;10(suppl_3):A168-A.
17. Lanfear AT, Hamandi M, Fan J, DiMaio JM, George TJ. Trends in HeartMate 3: What we know so far. J Card Surg. 2020;35(1):180-7.
18. Ettner SL. New evidence on the relationship between income and health. J Health Econ. 1996;15(1):67-85.
19. Hajat A, Kaufman JS, Rose KM, Siddiqi A, Thomas JC. Do the wealthy have a health advantage? Cardiovascular disease risk factors and wealth. Soc Sci Med. 2010;71(11):1935-42.
20. Ezzati M, Vander Hoorn S, Lawes CM, Leach R, James WP, Lopez AD, et al. Rethinking the ”diseases of affluence” paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med. 2005;2(5):e133.
21. Bosch L, Assmann P, de Grauw WJC, Schalk BWM, Biermans MCJ. Heart failure in primary care: prevalence related to age and comorbidity. Prim Health Care Res Dev. 2019;20:e79.
22. Katherine Lietz JWL, Abdallah G. Kfoury, Mark S. Slaughter, Marc A. Silver, Carmelo A. Milano, Joseph G. Rogers, Yoshifumi Naka, Donna Mancini, and Leslie W. Miller. Outcomes of Left Ventricular Assist Device Implantation as Destination Therapy in the Post-REMATCH Era. Circulation. 2007;116:497-505.
23. Cerier E, Lampert BC, Kilic A, McDavid A, Deo SV, Kilic A. To ventricular assist devices or not: When is implantation of a ventricular assist device appropriate in advanced ambulatory heart failure? World J Cardiol. 2016;8(12):695-702.
24. Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. JACC Heart Fail. 2017;5(2):110-9.
25. Cotts WG, McGee EC, Jr., Myers SL, Naftel DC, Young JB, Kirklin JK, et al. Predictors of hospital length of stay after implantation of a left ventricular assist device: an analysis of the INTERMACS registry. J Heart Lung Transplant. 2014;33(7):682-8.
26. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-43.
27. Marmot M. Social justice, epidemiology and health inequalities. Eur J Epidemiol. 2017;32(7):537-46.
Table 1: Values are reported as mean ± standard deviation for continuous variables. Categorical variables are represented as n (%). Between-group comparisons were performed for continuous data using T-test for parametric and Mann-Whitney U test for nonparametric variables, respectively. Categorical variables were compared using Chi squared test. p<0.001 considered for statistical significance per Holm-Bonferroni correction for multiple comparisons. p value considered significant <0.001 (bold). NS=Non-Significant.
Table 2: Values are reported as mean ± standard deviation and median [IQR 25-75] for parametric and non-parametric continuous variables, respectively. Categorical variables are represented as n (%). Between-group comparisons were performed for continuous data using T-test for parametric and Mann-Whitney U test for nonparametric variables, respectively. Categorical variables were compared using Chi squared test. p<0.001 considered for statistical significance per Holm-Bonferroni correction for multiple comparisons. p value considered significant <0.001 (bold). NS=Non-Significant.
Figure A: Number of left ventricular assist devices implanted per every calendar year by income. Average increase per year of the low-income group was 11% and for the high-income group was 8%.
Figure B: Median length of stay (LOS) in days in patients undergoing left ventricular assist device (LVAD) implantation by income per every calendar year. Variables were compared using Mann-Whitney U test with p<0.001 considered for statistical significance (Black X). Dots=Non-significant difference.
Figure C: Trend and comparison of inpatient all-cause mortality of patients undergoing left ventricular assist device (LVAD) by income per every calendar year. Variables were compared using Chi squared test with p<0.001 considered for statistical significance (Black X). Dots=Non-significant difference.